A Phase I Study on Tolerance and Safety of Vemurafenib Film-coated Tablets, Cetuximab Solution for Infusion and Camrelizumab Protocol(VCC) in the After Line Therapy of BRAF V600E Mutation/MSS Metastatic Colorectal Cancer
试验速览
- 阶段
- 1 期
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Evaluate tolerability and safety and identify the recommended Phase 2 dose(RP2D)
研究概览
简要总结
BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is the most common type, which is an important biomarker for predicting the prognosis and precise treatment efficacy of metastatic colorectal cancer (mCRC). The prognosis of metastatic colorectal cancer with BRAF V600E mutation is very poor, with OS of about 6-9 months. Previous studies have shown that single anti-BRAF inhibitor are ineffective, while multi-target inhibitions of Ras-Raf -MEK pathway is a possible effective strategy for BRAF V600E-mutant mCRC. Currently, the proven effective regimens include the VIC regimen (Vemurafenib + cetuximab + Irinotecan) and BEACON regimen (Encorafenib+ cetuximab +/- Binimetinib) from the SWOGS1406 study. Furthermore, BRAF inhibitor +MEK inhibitor combined with PD-1 monoclonal antibody has been shown to be an effective strategy in BRAF V600E-mutant malignant melanoma, which promote the study of the regimens for the treatment of BRAF V600E-mutant mCRC. Increasing basic and clinical studies have shown that cetuximab has ADCC effect, induces immunogenic cell death, promotes immune cell infiltration and other immunomodulatory effects, and has a synergistic effect with PD-1 monoclonal antibody in colorectal cancer. Based on those theories, we conducted the phase I study to explore the safety and preliminary efficacy of the regimen of Vemurafenib (BRAFi) plus cetuximab (EGFRi) combined with PD-1 monoclonal antibody in BRAF V600E-mutant /MSS type mCRC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years of age
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- •Participants must have histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, with clinical confirmation of unresectable and/or metastatic disease that is measurable according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria
- •Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to screening and confirmed by central laboratory. And confirmation of MSS or pMMR status from immunohistochemistry or PCR or NGS;
- •Prior treatment with at least one systemic treatment (chemotherapy or target therapy) for mCRC, and prior treatment did not include cetuximab
- •Adequate organ and marrow function:
- •①Hemoglobin (Hb) ≥ 90 g/L；Platelets (PLT) ≥ 75 x 10^9/L；Neutrophil ≥1.5 x 10^9/L
- •②Total bilirubin ≤ 1.5 x upper limit of normal (ULN)；Aspartate aminotransferase (AST) ≤3 x ULN ；Alanine aminotransferase (ALT) ≤3 x ULN
- •③Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance (determined as per Cockcroft-Gault) ≥ 50 mL/min at screening
- •④INR, APTT, and PT≤ 1.5 x ULN
- •⑤Serum albumin≥ 28 g/L
- •⑥ECG showed no evident abnormality
- •Written informed consent
排除标准
- •Known hypersensitivity or contraindication to any component of cetuximab or PD-1 monoclonal antibody or macromolecular protein reagent.
- •A history of other malignancies with a disease-free survival of less than 5 years, with the following exceptions: adequately treated basal or squamous cell skin cancer, carcinoma in-situ of the cervix, and gastrointestinal tumors treated curatively with endoscopic mucosectomy;
- •Any active autoimmune disease or a history of autoimmune disease
- •Use of immunosuppressive medications or glucocorticoid therapy ≤2 weeks prior to entry
- •Uncontrolled active infection requiring antibiotics
- •Known history of HIV infection or active hepatitis
- •Severe complications, including any of the following:
- •①Massive gastrointestinal bleeding, perforation, or gastrointestinal obstruction
- •②Symptomatic heart disease
- •③Uncontrolled diabetes and hypertension
- •④Uncontrolled diarrhea
- •Women who are pregnant or lactating and people who do not agree to avoid pregnancy
- •Patients with serious psychiatric that may interfere treatment.
- •Other conditions which are inappropriate to participate in the study confirmed by investigators.
研究组 & 干预措施
Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)
Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid
干预措施: Vemurafenib Oral Tablet [Zelboraf] (Drug)
Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)
Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid
干预措施: Cetuximab Injection [Erbitux] (Drug)
Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)
Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid
干预措施: Camrelizumab (Drug)
结局指标
主要结局
Evaluate tolerability and safety and identify the recommended Phase 2 dose(RP2D)
时间窗: Subjects will be treated and observed for dose-limiting toxicity(DLT) through the end of the first cycle (Days 1-28)
次要结局
- Disease Control Rate (DCR)(up to 24 weeks)
- Progression Free Survival (PFS)(up to 1 year)
- Overall Survival (OS)(up to 3 year)
- Preliminary efficacy(up to 1 year)
- Object Response Rate (ORR)(up to 24 weeks)
研究者
Meng Qiu
Clinical Professor
West China Hospital